Kura Oncology, Inc. (NASDAQ:KURA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Kura Oncology, Inc. (NASDAQ:KURA) have earned an average recommendation of “Moderate Buy” from the thirteen analysts that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $26.5714.

Several research firms recently commented on KURA. Wall Street Zen upgraded shares of Kura Oncology from a “sell” rating to a “hold” rating in a research report on Sunday, August 17th. Wedbush restated an “outperform” rating and set a $38.00 target price (up previously from $36.00) on shares of Kura Oncology in a research report on Friday, November 14th. Citigroup reaffirmed a “market outperform” rating on shares of Kura Oncology in a report on Friday, December 5th. Guggenheim began coverage on shares of Kura Oncology in a research report on Thursday, September 4th. They issued a “neutral” rating on the stock. Finally, UBS Group lifted their price objective on Kura Oncology from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday, November 14th.

Insider Activity at Kura Oncology

In other news, insider Mollie Leoni sold 15,485 shares of the business’s stock in a transaction on Friday, November 14th. The stock was sold at an average price of $11.18, for a total value of $173,122.30. Following the completion of the transaction, the insider directly owned 225,454 shares of the company’s stock, valued at $2,520,575.72. The trade was a 6.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Brian T. Powl sold 8,891 shares of the company’s stock in a transaction on Monday, September 29th. The shares were sold at an average price of $8.94, for a total value of $79,485.54. Following the completion of the sale, the insider owned 99,676 shares in the company, valued at $891,103.44. This represents a 8.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 122,675 shares of company stock valued at $1,196,657 in the last ninety days. 6.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Kura Oncology

Several hedge funds have recently modified their holdings of the company. BVF Inc. IL grew its holdings in shares of Kura Oncology by 202.0% during the first quarter. BVF Inc. IL now owns 7,754,129 shares of the company’s stock worth $51,177,000 after buying an additional 5,186,660 shares in the last quarter. Armistice Capital LLC boosted its position in Kura Oncology by 13.3% during the first quarter. Armistice Capital LLC now owns 6,572,000 shares of the company’s stock worth $43,375,000 after acquiring an additional 772,000 shares during the last quarter. Vanguard Group Inc. grew its stake in Kura Oncology by 2.2% in the 3rd quarter. Vanguard Group Inc. now owns 5,468,522 shares of the company’s stock worth $48,396,000 after acquiring an additional 120,197 shares during the period. EcoR1 Capital LLC grew its stake in Kura Oncology by 59.1% in the 2nd quarter. EcoR1 Capital LLC now owns 4,200,000 shares of the company’s stock worth $24,234,000 after acquiring an additional 1,559,702 shares during the period. Finally, Jacobs Levy Equity Management Inc. raised its holdings in Kura Oncology by 101.6% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,224,590 shares of the company’s stock valued at $19,688,000 after acquiring an additional 1,121,228 shares during the last quarter.

Kura Oncology Price Performance

Shares of NASDAQ:KURA opened at $10.22 on Monday. The business’s 50 day simple moving average is $10.59 and its 200-day simple moving average is $8.24. The firm has a market capitalization of $889.34 million, a price-to-earnings ratio of -4.12 and a beta of 0.21. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.12 and a quick ratio of 5.12. Kura Oncology has a 12 month low of $5.41 and a 12 month high of $12.49.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.28). The firm had revenue of $20.75 million for the quarter, compared to analyst estimates of $17.48 million. Kura Oncology had a negative return on equity of 65.42% and a negative net margin of 208.48%. As a group, equities analysts forecast that Kura Oncology will post -2.44 earnings per share for the current fiscal year.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.